Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of osteosarcoma.

Jeremy Whelan1, Beatrice Seddon, Martha Perisoglou

  • 1Department of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK. jeremy.whelan@uclh.nhs.uk

Current Treatment Options in Oncology
|October 13, 2006
PubMed
Summary

Improving osteosarcoma cure rates is challenging, with limited treatment advances. The European and American Osteosarcoma (EURAMOS) 1 trial offers a new era for clinical investigation and evaluating new strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.

British journal of cancer·2026
Same author

Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.

BMJ open·2024
Same author

The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma.

International journal of radiation oncology, biology, physics·2024
Same author

Heritable defects in telomere and mitotic function selectively predispose to sarcomas.

Science (New York, N.Y.)·2023
Same author

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.

Lancet (London, England)·2022
Same author

Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235].

European journal of cancer (Oxford, England : 1990)·2022

Area of Science:

  • Oncology
  • Orthopedic Surgery
  • Clinical Trials

Background:

  • Osteosarcoma treatment outcomes have seen minimal improvement over the past two decades.
  • Current chemotherapy regimens are particularly arduous, and primary tumor treatment often results in permanent disability.

Purpose of the Study:

  • To introduce the European and American Osteosarcoma (EURAMOS) 1 trial as a new international cooperative effort.
  • To highlight the trial's potential for generating biologic insights and accelerating the evaluation of novel therapeutic strategies for osteosarcoma.

Main Methods:

  • Initiation of a randomized clinical trial, EURAMOS 1, across Europe and the United States.
  • International cooperation to facilitate the study of osteosarcoma treatment strategies.

Main Results:

  • The EURAMOS 1 trial represents a significant advancement in clinical investigation for osteosarcoma.
  • The study aims to provide valuable biologic insights and expedite the assessment of investigational treatments.

Conclusions:

  • Osteosarcoma management demands a multidisciplinary specialist team.
  • Enrollment in well-designed clinical trials, such as EURAMOS 1, is recommended for patients whenever feasible.

Related Experiment Videos